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1. Introduction
   Diabetes is a prototypical, growing, costly chronic non-
communicable disease (NCD) causing increasing morbidity 
and mortality worldwide, often disproportionately hurting 
the poor and young sub-populations in developing 
countries[1]. Globally there are 366 million people currently 
known to have diabetes which is estimated to grow to 552 
million by 2030 with 80% of all people with diabetes living 
in the developing world[2]. An estimated 61.3 million people 
in India have diabetes and the number is projected to reach 
101.2 million by 2030. The pathophysiology of diabetes 
involves a very complex cascade of several interrelated 
mechanism. Elevated blood glucose induced microvascular 
and macrovascular changes, such as atherosclerosis, 
retinopathy, nephropathy, coronary artery disease, cerebral 
vascular disease, and peripheral artery disease[3], the 
reasons for injury related to hyperglycemia is increased 
polyol pathway flux, increased glycation of proteins 
(enzymatic or non enzymatic) and increased hexosamine 
pathway flux[4]. Among the above stated possibilities, 
glycosylation of proteins has been the prime subject of 
much interest. In the diabetic state, glucose is used by the 
insulin independent pathways, leading to the synthesis of 
oligosaccharide moieties of glycoprotein.
   Glycoproteins can be simply defined as proteins that have 
carbohydrate moiety covalently attached to their peptide 
portion. They have multiple and complex function and are 
found as enzymes, hormones, blood group substances and as 
constituents of extracellular membranes[5]. The commonest 
glycoproteins are those in which the carbohydrate is 
linked to the protein by glycosyl linkages, usually hexose, 
hexosamine, fucose and sialic acid, joined together 
covalently linked to polypeptide chain. Hyperglycemia in 
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experimental diabetic rats leads to a decreased utilization of 
glucose by insulin dependent pathways, thereby enhancing 
the formation of glycoproteins[6]. At the cell surface or 
inside the cells, the glycoprotein components such as fucose 
and sialic acid form specific structures, called glycanic 
chains covalently linked to lipids or proteins. An increase 
in the biosynthesis or a decrease in the metabolism of 
glycoproteins could be related to the deposition of these 
materials in the basal membrane of pancreatic cells. 
Alterations in glycoproteins level leads to the pathogenesis 
of diabetes mellitus. Many studies confirm the involvement 
of glycoproteins in diabetic complications[7].
   Plants constitute an important source of active natural 
products which differ widely in terms of structure and 
biological properties[8]. They have a remarkable role in the 
traditional medicine in different countries. Recently, plants 
and their active components have been widely used in the 
treatment of diabetes. Plant derived phenolic compounds 
have a high potential for lowering blood glucose levels. 
Syringic acid (4-hydroxy-3,5-dimethoxybenzoic acid; Fig. 
1) is an active phenolic compound isolated from Alpinia 
calcarata Roscoe[9]. The leaves of Alpinia calcarata Roscoe 
are a well-known traditional indian ayurveda medicine and 
have been used to treat for diabetes. Since, no systematic 
studies exist in the literature on the effect of syringic acid 
on glycoprotein components in diabetes, in this view, the 
aim of the present study was to establish the antidiabetic 
effect of syringic acid and also mediated through its 
salubrious effect on plasma and tissue glycoproteins in 
alloxan induced diabetic rats. The outcome, we believe, 
might provide important information about its usefulness as 
a therapeutic agent for the treatment of diabetes and related 
complications.
O
OH
Figure 1. Structure of syringic acid.
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2. Materials and methods
2.1. Animals
   Male Albino Wistar rats weighing around  180-200 g 
were procured from the  Adhiparasakthi College of Arts 
and Science, Kalavai, Tamilnadu and were housed under 
standard  vivarium  conditions  (12  h  light  and  dark  cycle, 
relative  humidity  55%). The  rats were given normal  pellet 
diets  (Hindustan  Lever  Ltd,  Bangalore, India) and water 
ad  libitum. The experimental design was performed in 
accordance with the current ethical norms approved  by the 
Ministry of  Social Justices and  Empowerment, Government 
of India and Institutional Animal Ethics Committee 
Guidelines (No.1282/ac/09/CPCSEA) for the investigation of 
experimental pain in conscious animals.
2.2. Chemicals
   All the chemicals used in this experiment were obtained 
from Sigma Chemical Company (St Louis, MO, USA), Hi 
Media (Mumbai, India), and SD-Fine Chemicals (Mumbai, 
India). All chemicals used were of analytical grade.
2.3. Induction of diabetes
   Preparation of alloxan-induced diabetic rats Diabetes 
was induced in rats that had been fasted for 12 h by 
intraperitoneal injection of 150 mg/kg body weight (bw) 
of alloxan, freshly dissolved in sterile normal saline 
immediately before use to give a concentration of 30 g/L. The 
diabetic state was assessed by measuring non-fasting serum 
glucose concentration 72 h after alloxan treatment. The rats 
with a serum glucose level above 300 mg/dL, as well as with 
polyuria, polydipsia, and polyphagia were selected for the 
experiment.
2.4. Experimental design
   The animals were randomly divided into four groups of six 
animals in each group (12 diabetic surviving and 12 normal). 
Syringic acid was dissolved in vehicle solution of of 0.9% 
saline and syringic acid (50 mg/kg b.w) were administered 
orally using an intragastric tube for a period of 30 d.
   Group I: Normal control (vehicle treated; saline: 1 mL/kg 
b.w)
    Group II: Normal + syringic acid (50 mg/kg b.w) 
    Group III: Diabetic control 
    Group IV: Diabetic + syringic acid (50 mg/kg b.w)
   After 30 d of treatment, the animals were deprived of 
food overnight, anaesthetized and sacrificed by cervical 
decapitation. Blood sample was collected in a tube 
containing potassium oxalate and sodium fluoride (3:1) for 
the estimation of glucose, insulin and glycoproteins. Liver 
and kidney were dissected out, washed in ice-cold saline, 
patted dry and weighed. 
2.5. Biochemical assays
2.5.1. Determination of plasma glucose, insulin and 
C-peptide
   Measurements of plasma glucose and insulin were 
estimated colorimetrically using commercial diagnostic kits 
(Sigma Diagnostics (I) Pvt Ltd, Baroda, India). Plasma insulin 
was assayed by ELISA using a Boehringer-Mannheim 
kit with an ES300 Boehringer analyzer (Mannheim, 
Germany). Both the analyses were done according to the 
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manufacturer’s instructions. Connecting peptide (C-peptide) 
was determined using Rat C-Peptide RIA Kit from LINCO 
Research, Missouri, USA. The Millipore Rat C-Peptide assay 
utilized 125I-labelled Rat C-Peptide antiserum to determine 
the level of C-peptide in plasma by the double antibody 
technique.
2.5.2. Extraction of glycoproteins
   To 0.1 mL of plasma, 5.0 mL of methanol was added, mixed 
well and centrifuged for 10 min at 3 000×g. The supernatant 
was decanted and the precipitate was again washed with 
5.0 mL of 95% ethanol, recentrifuged and the supernatant 
was decanted to obtain the precipitate of glycoproteins. 
This was used for the estimation of hexose and hexosamine. 
For extraction of glycoproteins from the tissues, a known 
weight of the tissue was homogenized in 7.0 mL of methanol. 
The contents were filtered and homogenized with 14.0 
mL of chloroform. This was filtered and the residue was 
successively homogenized in chloroform-methanol (2:1 v/v) 
and each time the extract was filtered. The residue (defatted 
tissues) was obtained and the filtrate decanted. A weighed 
amount of defatted tissue was suspended in 3.0 mL of 2 N 
HCl and heated at 90 曟 for 4 h. The sample was cooled and 
neutralized with 3.0 mL of 2 N NaOH. Aliquots from this were 
used for estimation of fucose, hexose, hexosamine and sialic 
acid.
2.5.3. Determination of glycoproteins
   The plasma and tissue hexose content was estimated by 
the method of Niebes[10], sialic acid in plasma and tissues 
were estimated by the method of Warren[11] and hexosamine 
by the method of Wagner[12]. Fucose was estimated by the 
method of Dische and Shettles[13], respectively.
2.6. Statistical analysis
   Data presented as means依 SD and subjected to statistical 
significance were evaluated by one way analysis of variance 
(ANOVA) using SPSS Version 13.0 (SPSS, Cary, NC, USA) and 
the individual comparisons were obtained by Duncan’s[14] 
multiple range test (DMRT). Values were considered 
statistically significant when P<0.05.
3. Results 
3.1. Effect of syringic acid on the levels of plasma glucose 
and insulin 
   Figure 2a and 2b shows the level of plasma glucose and 
insulin in control and experimental diabetic animals. There 
was a significant (P<0.05) elevation in plasma glucose 
level with significant (P<0.05) decrease in plasma insulin 
levels in alloxan diabetic rats, compared with normal 
rats. Administration of syringic acid tended to bring blood 
glucose and plasma insulin towards near normal levels. The 
plasma glucose and insulin levels of normal rats were not 
altered when administered with syringic acid (50 mg/kg b.w).
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3.2. Effect of syringic acid on the levels of plasma 
glycoproteins and C-peptide
   Table 1 shows the changes in the level of plasma 
glycoproteins and C-peptide of control and experimental 
Table 1. 
Effect of syringic acid on plasma glycoprotein and C-peptide levels in normal and experimental rats.
Groups Hexose (mg/dL) Hexosamine (mg/dL) Fucose (mg/dL) Sialic acid (mg/dL) C-peptide (pmol/L)
Normal    90.30 依 6.88* 72.17 依 5.50* 29.91 依 2.28*  55.39 依 4.22* 235.30 依 17.92*
Normal + syringic acid (50 mg/kg)    87.97 依 6.73* 71.36 依 5.46* 27.35 依 2.09*  54.31 依 4.16* 239.03 依 18.30*
Diabetic control   144.34 依 11.05† 99.08 依 7.58† 44.71 依 3.42† 75.33 依 5.77† 65.29 依 4.97†
Diabetic + syringic acid (50 mg/kg) 103.33 依 7.91‡ 82.85 依 6.34‡ 34.29 依 2.62‡ 61.45 依 4.70‡ 198.47 依 15.19‡
Values are given as means依 S.D. for six rats in each group. Values in a column not sharing a common superscript symbol (* -‡) differ 
significantly at P < 0.05. Duncan’s Multiple Range Test (DMRT).
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rats. There was a significant (P<0.05) increase of plasma 
glycoproteins with significant (P<0.05) decrease in plasma 
C-peptide levels in diabetic rats when compared to 
normal control rats. Oral administration of syringic acid to 
diabetic rats resulted in significant (P<0.05) reduction of 
glycoproteins and significant (P<0.05) increase of C-peptide 
in the plasma when compared to diabetic untreated rats. 
3.3. Effect of syringic acid on the levels of tissue glycoproteins 
   The levels of liver and kidney glycoprotein of control and 
experimental rats were shown in Tables 2 and 3. The level of 
hexose, hexosamine and fucose were significantly (P<0.05) 
increased whereas the level of sialic acid was significantly 
(P<0.05) decreased and those levels were brought back to 
near normal by treatment with syringic acid.
4. Discussion 
   Alloxan is the most commonly employed agent for the 
induction of diabetes in experimental animal model. There 
is increasing evidence that alloxan causes diabetes by rapid 
depletion of β-cells by DNA alkylation and accumulation of 
cytotoxic free radicals that is suggested to result from initial 
islet inflammation, followed by infiltration of activated 
macrophages and lymphocyte in the inflammatory focus. 
It leads to a reduction in plasma insulin concentration 
leading to a stable hyperglycemia state[15]. In this study 
also significant hyperglycemia was achieved after alloxan 
injection. The optimum dose of syringic acid was fixed by 
administering graded doses of syringic acid to diabetic rats 
for different time periods and the minimum effective dose 
for 30 d which caused maximum hypoglycemic activity 
and non-toxic nature was chosen (50 mg/kg b.w) for the 
present study (data not shown). The antidiabetic effect of 
syringic acid  may be due to the increased release of insulin 
from the existing β-cells and/or  regenerated β-cells 
of pancreas, restored insulin sensitivity or inhibition of 
intestinal absorption of glucose or  enhanced  the  utilization 
of glucose by peripheral tissues. These results are in 
agreement with pari and Rajarajeswari[16]who reported 
that administration of coumarin, a phenolic compound to 
diabetic rats  significantly decreased the glucose level  to 
near normal through enhanced release of insulin from  the 
existing β-cells. Since, protective role of syringic acid 
on glycoprotein components in diabetes remain to be 
investigated. In the present work, we demonstrated that 
syringic acid attenuated the elevation of glycoprotein 
components in normal  and  diabetic  rats.
   C-peptide, a cleavage product of proinsulin, is secreted 
by pancreatic β-cells in equimolar amounts along with 
insulin. C-peptide has been considered an inert by-product 
of insulin synthesis and has also been of great value in the 
understanding of the pathophysiology of type 1 and type 2 
diabetes mellitus[17]. Therefore, we checked the C-peptide 
levels since it is secreted in equimolar amounts compared 
to insulin and have a much longer half life than insulin. 
Moreover, C-peptide may interact with insulin signal 
transduction and also be suggested as a new therapeutic 
implications for long-term complications of diabetes[18]. In 
the present study, the significant decrease in the plasma 
glucose levels and significant increase in plasma insulin 
and more importantly the C-peptide levels of syringic 
acid treated rats indicate that this compound augmented 
the conversion of pro-insulin to insulin in addition to the 
augmented glucose transport and insulin secretion. These 
results suggested that syringic acid may increase insulin 
secretion of pancreatic β-cells and normalize the plasma 
glucose level.
   Diabetes mellitus is often associated with the development 
of vascular degenerative complications affecting both 
large vessels and the microvasculature. Several studies 
have emphasized the multiplicity of disturbances affecting 
the metabolism of carbohydrates, proteins and lipids in 
diabetes[19]. Glycation is a nonenzymatic reaction of glucose 
and other saccharide derivatives with proteins, nucleotides 
and lipids. Glycation is considered to be one of the key 
mechanisms responsible for the long-term consequences 
of diabetes. Glycation occurs inside and outside of cells; 
Table 2. 
Effect of syringic acid on liver glycoprotein levels in normal and experimental rats (mg/g defatted tissue).
Groups Hexose Hexosamine Fucose Sialic acid
Normal   26.18 依 1.99*  11.25 依 0.86* 15.36 依 1.17* 9.47 依 0.72*
Normal +  syringic acid (50 mg/kg)   25.34 依 1.94*  10.79 依 0.83* 16.50 依 1.26* 9.92 依 0.76*
Diabetic control  46.51 依 3.56†   20.35 依 1.56† 27.36 依 2.85† 4.48 依 0.34†
Diabetic +  syringic acid (50 mg/kg)  32.56 依 2.49‡  15.23 依 1.17‡ 19.36 依 1.48‡ 7.02 依 0.54‡
Values are given as means依 S.D. for six rats in each group. Values in a column not sharing a common superscript symbol (* -‡) differ 
significantly at P<0.05. Duncan’s Multiple Range Test (DMRT).
Table 3. 
Effect of syringic acid on kidney glycoprotein levels in normal and experimental rats (mg/g defatted tissue).
Groups Hexose Hexosamine Fucose Sialic acid
Normal 24.16 依 1.84* 16.85 依 1.28* 13.67 依 1.04* 9.03 依 0.69*
Normal +  syringic acid (50 mg/kg) 22.99 依 1.76* 15.29 依 1.17* 14.29 依 1.09* 9.28 依 0.71*
Diabetic control 43.71 依 3.35† 33.28 依 2.55† 30.60 依 2.34† 5.26 依 0.40†
Diabetic +  syringic acid (50 mg/kg) 29.32 依 2.24‡ 22.25 依 2.00‡ 18.89 依 1.45‡ 7.02 依 0.54‡
Values are given as means依 S.D. for six rats in each group. Values in a column not sharing a common superscript symbol (* -‡) differ 
significantly at P<0.05. Duncan’s Multiple Range Test (DMRT).
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Glycation of cellular proteins produces changes in structure 
and loss of enzymatic activity. The elevated levels of plasma 
glycoproteins in diabetic rats could be a consequence of 
abnormal carbohydrate metabolism. Insulin deficiency 
and high levels of plasma glucose in diabetic condition 
may result in an increased synthesis of glycoproteins[20]. 
The increase in plasma glycoprotein components has been 
associated with the severity of diabetes. The elevation in 
the levels of plasma glycoprotein components might be due 
to secretion from cell membrane glycoconjugates into the 
circulation[21]. In this study, we have observed the increased 
levels of hexose, hexosamine, fucose and sialic acid in the 
plasma of alloxan induced diabetic rats. Administration of 
syringic acid ameliorates the levels of plasma glycoproteins 
near to normal. Our results are in harmony with Sundaram 
et al[22]who reported that iridoid glucoside, improved plasma 
glycoprotein components in experimantal diabetic rats.
   Liver is one of the chief storage organs for glucose reserve 
in the body and plays a crucial role in maintenance of 
blood glucose homeostasis, because it consents to amass 
the superfluous blood glucose and to demobilize it in 
hypoglycemic states. Chronic hyperglycemia impedes normal 
inhibition of hepatic glucose production persuaded by an 
acute escalation of blood glucose level[23]. Liver is primarily 
responsible for producing a large amount of glycoproteins 
present in blood. Diabetic nephropathy is one of the major 
microvascular complications and is a leading cause of end-
stage renal disease, is characterized by the protuberance of 
the glomerular mesangium due to amassing of extracellular 
matrix proteins synthesized by the mesangial cells with 
basement membrane thickening, glomerular and tubular 
hypertrophy, glomerulosclerosis and tubulointerstitial 
fibrosis[24]. The pathogenesis of diabetic nephropathy is 
multifactorial in which chronic hyperglycemia plays a 
crucial role[25]. The excess availability of glucose in the 
hyperglycemic state accelerates the synthesis of basement 
membrane components, (glycoproteins) and this leads to 
the thickening of capillary basement membrane[26]. The 
luminal surface of epithelial cells in kidney tubules is also 
lined with a thick carbohydrate rich glycoprotein layer. 
Stimulation of kidney protein synthesis may contribute to 
explain the increase in the synthesis of glycoproteins as well 
as the renal hypertrophy that occurs early in diabetes[27]. The 
biochemical markers, hexose, hexosamine, fucose and sialic 
acid have been measured in the liver and kidney because 
liver is responsible for synthesis of all major proteins, which 
are then secreted into the blood.  
   Hexosamine a nitrogenous sugar in which an amino group 
replaces a hydroxyl group. It is an excellent precursor 
for use in the investigation of synthesis of plasma and 
tissue glycoproteins. The level of hexosamine, increased 
significantly in the plasma and tissues of diabetic rats, which 
may be due to insulin deficiency, this leads to depressed 
utilization of glucose by insulin-dependent pathway, there 
by enhancing the formation of hexose and hexosamine[28]. In 
diabetic rats treated with syringic acid significantly lowered 
hexosamine, which might be due to increased secretion 
of insulin. Our results are find in line with the study of 
reduced hexosamine by improved secretion of insulin in 
tetrahydrocurcumin and chlorogenic acid treated diabetic 
rats[29].
   Fucose is member of a group of essential sugars that the 
body requires for functioning of cell to cell communication 
and its metabolism appear to be altered in various disease 
conditions such as diabetes mellitus[30]. A rise in fucose 
levels could be due to increased glycosylation in the diabetic 
state. In diabetes, three proteins (haptoglobin, a1 acid 
glycoprotein and a1-antitrypsin) synthesized in the liver 
are mainly responsible for the increase in fucose levels. The 
metabolism and synthesis of these proteins may be altered in 
diabetes leading to changes in plasma in the hyperglycemic 
state accelerates the synthesis of glycoproteins. Due to 
increased glycosylation in the diabetic state the fucose 
levels could be increased. Treatment with syringic acid 
had restored fucose level to near normal, which could be 
due to improved glycemic status in plasma and tissues. 
These results are agreement with pari and Rajarajeswari[7]
who reported that coumarin a phenolic compound improves 
fucose level in diabetic rats.
   Sialic acid is an acute phase protein derived from 
neuraminic  acid which forms terminal  sugar  o f 
carbohydrates taking part in the glycoprotein structure[31]. 
Sialic acids play a role in cell-cell recognition, protein 
targeting, protease resistance, conformational stabilization, 
adhesion, and intracellular signaling events in biological 
systems. In diabetes mellitus, the tissue concentration of 
sialic acid was found to decrease significantly. The decrease 
in the content of sialic acid in tissues may be due to the 
utilization for the synthesis of fibronectin, which contains 
sialic acid residues in the core structure. The synthesis 
of fibronectin was also reported to increase significantly 
in various tissues of diabetic patients and rats. In our 
study, a significant increase in total sialic acid levels in 
the plasma was observed when compared with the control 
group. Various factors might cause an elevation in the 
concentration of plasma sialic acid. Among these factors, the 
first is an increase in the synthesis of sialic acid in insulin-
independent tissues, such as the liver and the brain, and 
the second is an increase in the activity of sialytransferase, 
which transfers the sialic acid residues to the glycolipids 
and glycoproteins[32]. In our study, administration of syringic 
acid increased the content of sialic acid in the tissues and 
decreased the sialic acid level in the plasma by enhancing 
the secretion insulin level. Insulin has been found to 
inhibit cytokine-induced acute phase protein synthesis in 
rat hepatic cell. This may, consequently, account for the 
decreased plasma sialic acid levels in the alloxan induced 
diabetic rats. Previous studies show that diosmin, produce 
the same effect in experimental diabetic rats[21].
   From the above findings, we conclude that syringic 
acid decreased hyperglycemic state in alloxan induced 
diabetic rats might have been responsible for the decrease 
of glycoproteins in plasma, liver and kidney. Syringic acid 
may have beneficial effects in diabetes mellitus by the 
enhancement of insulin action and C-peptide, as evident 
by the decreased level of plasma glucose in diabetic rats. 
The observed effect of syringic acid on reversing the adverse 
effects of hyperglycemia provides an insight into the 
pathogenesis of diabetic complications and may be used to 
advantage in therapeutic approaches.
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